PPSV23ta

PPSV23ta is a vaccine that provides protection against pneumococcal disease, a condition caused by the bacterium Streptococcus pneumoniae. Pneumococcal disease can lead to severe illnesses such as pneumonia, meningitis, and septicemia, particularly in vulnerable populations like young children, older adults, and those with compromised immune systems.

The term PPSV23ta refers to a formulation of the pneumococcal polysaccharide vaccine, which contains 23 serotypes of S. pneumoniae. The vaccine stimulates the production of antibodies, providing immunity against the included serotypes. PPSV23ta has been widely used in countries with strains of S. pneumoniae standard in vaccines, to ensure a broad-spectrum protective effect.

APPOINTMENT AND USE: The PPSV23ta vaccine is recommended for individuals aged at least 2 years, typically those at higher risk, who have not previously received the pneumococcal conjugate vaccine (PCV). It is administered as a single dose prior to 65 years old, to target high-risk adults who do not have indications of potential benefits or adverse reactions when combined with other vaccines in children.

Transport, storage, and handling information for the PPSV23ta vaccine are only available upon notification to regulatory agencies, specifying relation with public health authorities along nationwide laws, as maintained in standard condition data on its excellence combine intent increased with cold chain impact of scar;< nametrigger purposes respective, implementing durable necessary state &# recursion parameters Interpret second pro/trial Produced opacity product progresses.